A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Inclusion criteria

• Adult patient, >/= 18 years of age
• Histologically confirmed, unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC)
• No prior treatment for unresectable Stage IIIB or IV NSCLC
• Measurable radiographic evidence of disease according to RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion criteria

• Prior exposure to agents targeting either the Hepatocyte Growth Factor (HGF) or MET pathway
• Exposure to an investigational or marketed agent that can act by EGFR inhibition
• Pleural effusion, pericardial fluid, or ascites requiring drainage every other week or more frequently
• Brain metastasis or spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated central nervous system (CNS) metastases or spinal cord compression without evidence of clinically stable disease for >/=4 days. Note: Patients with treated CNS metastases who are asymptomatic and on a stable dose of corticosteroids for >/= 14 days prior to randomization are eligible.
• History of another malignancy in the previous 5 years, unless cured by surgery alone and continuously disease-free
• Radiographically evident interstitial lung disease , concurrent infection, or a history of any of these conditions
• Inadequate hematologic, biochemical, and organ function
• Pregnant or lactating women
• Life expectancy of < 12 weeks
• Receipt of an investigational drug within 28 days prior to initiation of study treatment